CHP
AVDL

Cable Hill Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Cable Hill Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$1K – 779
2018
Q2 		$1K Hold
100
– – ﹤0.01% 855
2018
Q1 		$1K Buy
+100
New +$880 ﹤0.01% 853

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cable Hill Partners's AVDL Position: Q3 2018 in Review

Cable Hill Partners sold out of Avadel Pharmaceuticals (AVDL) in Q3 2018, closing a stake of 100 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in AVDL in Q1 2018 and held it in 2 quarters. The position peaked at $1K in Q2 2018. 65 funds tracked by Wall St. Rank hold AVDL as of Q3 2018.

  • Cable Hill Partners reported no remaining Avadel Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cable Hill Partners sold 100 Avadel Pharmaceuticals shares in Q3 2018, an estimated $1K.
  • Cable Hill Partners first reported a position in Avadel Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Cable Hill Partners's Avadel Pharmaceuticals position peaked at $1K in Q2 2018.
  • 65 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.